ICLR ICON PLC
Price Chart
Executive Summary
ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committee investigation that found improper revenue recognition and related control failures. Key corrections include a $92.7M revenue overstatement for FY2024 and a $65.3M overstatement for FY2023. Management disclosed material weaknesses in internal controls over financial reporting, and the company recorded a $364.2M goodwill impairment (Data Solutions) and a $101M impairment of other non-financial assets. The filing also notes the disposal of Symphony Health Solutions on May 8, 2026, and a Nasdaq deficiency notice (from the delayed 20-F) received one day prior.
Actionable Insight
The restatement confirms systemic revenue recognition failures and material control weaknesses. Though FY2025 revenue inched up 0.8%, operating income ex-impairments fell ~18% YoY, costs rose, and the $750M buyback consumed cash. With a Nasdaq deficiency notice, the Oct 2025 restructuring, and a class-action lawsuit pending, this is a profoundly negative signal for ICON's accounting credibility and near-term equity performance. Monitor the Q2 2026 6-K amendment for restated quarterly data and the SEC investigation outcome.
Key Facts
- FY2025 revenue: $8,251M vs FY2024 restated $8,189M (0.8% increase).
- FY2025 GAAP net income: $229M vs FY2024 restated $739M (-69%).
- FY2025 GAAP EPS diluted: $2.90 vs FY2024 restated $8.90.
- Goodwill impairment charge: $364.2M (Data Solutions unit).
- Impairment of non-financial assets: $101M.
- Revenue restated: FY2024 down $92.7M, FY2023 down $65.3M (improper revenue recognition).
- Net income restated: FY2024 down $52.3M, FY2023 down $58.1M.
- Material weaknesses disclosed in internal controls (tone at the top, revenue recognition).
- FY2025 operating income: $442.8M (5.4% margin) vs FY2024 restated $1,032.4M (12.6% margin).
- Share buyback in FY2025: $750M (4,504,330 shares at avg. $166.51).
- Debt at Dec 31, 2025: $3,402.4M net (73% fixed rate).
- Nasdaq deficiency notice received May 26, 2026 due to late 20-F filing.
- Symphony Health Solutions disposed May 8, 2026 for HealthVerity equity and $37.5M cash.
- $500M Bridge Secured Credit Facility entered April 27, 2026 to refinance 2026 Notes.
- Unaudited Obligor Group revenue FY2025: $7,458M; net income: $697M.
Financial Impact
Revenue overstated by ~$158M cumulatively over FY2023-2024. FY2025 GAAP operating margin collapsed to 5.4% from 12.6% due to $465M in impairment charges. The delayed filing triggered a Nasdaq deficiency notice.
Risk Factors
- Potential SEC enforcement action and shareholder lawsuits beyond the consolidated class action.
- Nasdaq delisting if 20-F compliance is not restored within the cure period.
- Further credit rating downgrade (Moody's already shifted outlook to stable from positive in Feb 2026).
- Additional impairment charges if Data Solutions revenue continues to decline.
- Execution risk on the remediation plan for material weaknesses; further restatements possible.
- $500M 2026 Notes maturity in July 2026 — bridge facility provides liquidity but adds leverage.
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001628280-26-038487 |
| Exhibit: exhibit212.htm | 0001628280-26-038487 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
13d ago
|
6-K
| $136.80 $143.90 | ▼ −5.19% | ▼ −5.24% | $152.24 (−11.29%) |
|
May 27, 2026
13d ago
|
20-F
| $136.80 $152.80 | ▼ −11.70% | ▼ −11.38% | $152.24 (−11.29%) |
|
May 26, 2026
14d ago
|
6-K
| $118.45 $143.90 | ▼ −21.49% | ▼ −21.02% | $152.24 (−28.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access